TrialJournal of gastroenterology2018

Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND study.

Yoshikazu Kinoshita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.